Clinical Trial Update: A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 [Phase 3]

View source ↗

Summary

Phase 3 extension study in chronic lymphocytic leukemia/small lymphocytic lymphoma evaluating duvelisib with ofatumumab has completed enrollment and results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: SecuraBio | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2023-02-21